Related Experiment Video
Updated: Apr 24, 2026
07:59
Murine Full-thickness Skin Transplantation
Published on: January 2, 2017
20.0K
Sirolimus: a therapeutic advance for dermatologic disease
T Peters1, D Traboulsi, L A Tibbles
1Faculty of Medicine, University of Calgary, Calgary, AB, Canada.
Skin Therapy Letter
|September 5, 2014
Summary
Sirolimus (SRL), an mTOR inhibitor, is approved for preventing kidney transplant rejection and shows promise for skin conditions. Emerging research suggests SRL and related rapalogs may also combat age-related diseases.
Area of Science:
- Immunology
- Pharmacology
- Gerontology
Background:
- Sirolimus (SRL), a mammalian target of rapamycin (mTOR) inhibitor, was FDA-approved in 1999 for renal transplant recipients.
- SRL exhibits potent immunosuppressant, anti-angiogenic, and anti-proliferative effects.
- Compared to other immunosuppressants, SRL has a reduced risk of renal, neurologic, and lymphoproliferative complications.
Purpose of the Study:
- To review the established and emerging therapeutic applications of sirolimus.
- To highlight SRL's potential in treating dermatologic conditions and age-related diseases.
Main Methods:
- Literature review of sirolimus (SRL) applications.
- Analysis of SRL's pharmacological properties (immunosuppressant, anti-angiogenic, anti-proliferative).
- Examination of recent findings on mTOR inhibitors and lifespan extension.
Main Results:
- SRL is a recognized treatment for angiofibromas, Kaposi's sarcoma, and other skin disorders.
- mTOR inhibitors have demonstrated lifespan extension in mouse models.
- Sirolimus and rapamycin analogs (rapalogs) are being investigated for age-related disease prevention.
Conclusions:
- Sirolimus is a valuable immunosuppressant with established efficacy in transplantation.
- SRL's anti-proliferative and anti-angiogenic properties support its use in various skin conditions.
- Emerging evidence positions sirolimus and rapalogs as potential interventions for age-related diseases.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
744
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
744
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
686
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
686
01:16Therapeutic Drug Monitoring: Overview and Classification
626
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
626
01:29Drugs for Treatment of Ulcerative Colitis in IBD
698
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
698
03:03mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
867
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
867